Multi-national Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Non-Communicable Respiratory Diseases, including Underrepresented Populations (IICS4all 2027)
- Entidad convocante:
- National funding agencies from participating countries
- Categoría:
- Altres
- Ámbito:
- Inicio:
- Plazo interno:
- Plazo real:
- Cuantía:
- check specific conditions per country
- Descripción:
-
The ERA4Health Partnership, co-funded under Horizon Europe, launches a Joint Transnational Call to support multinational Investigator-Initiated Clinical Studies (IICS).
This two-stage call funds:
- Pragmatic, phase III, randomized controlled, multinational interventional clinical studies.
- Comparative-effectiveness studies and/or drug repurposing studies of off-patent drugs.
- Research in cardiovascular diseases, metabolic disorders, autoimmune diseases, and non-communicable respiratory diseases.
- Studies that ensure inclusivity, diversity, and the consideration of sex-, gender-, age-, and other diversity-related aspects.
- Projects with a maximum duration of 48 months.
Additional funding of up to 15% of the consortium budget may be requested for cross-cutting trial management activities through ECRIN.
Objective: To generate robust multinational clinical evidence that improves patient outcomes, clinical practice, healthcare decision-making, and health system sustainability in major chronic disease areas.
a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }
Pre-proposal (Stage 1) deadline 14/01/2027, 12:00 CET Full proposal (Stage 2) deadline 14/06/2027, 12:00 CEST - Requisitos
-
Transnational consortia involving eligible partners from a minimum of 3 and a maximum of 5 participating countries.
- Maximum may increase to 6 countries if Slovakia is included as an underrepresented country.
- At least two eligible partners must be from different EU Member States or Horizon Europe Associated Countries participating in the call.
- A maximum of 3 self-funded collaborators is allowed.
- One Coordinating Investigator must be designated.
- Only a single sponsor per consortium is allowed.
- Principal Investigators may participate in only one proposal.
- Studies must be phase III pragmatic randomized controlled multinational IICS.
- Comparative-effectiveness studies must compare approved/existing healthcare interventions.
- Drug repurposing studies must involve approved off-patent medicines.
- Clinical studies with direct commercial purposes are not eligible.
- Splicitud
-
In case of interest, please click on 'm'interessa' and we will contact you.
